Mebeverina Tarbis

Mebeverine Hydrochloride, the active ingredient in Mebeverina Tarbis, is an antispasmodic presented as an oral formulation for oral use. It is indicated for the relief of abdominal pain and spasm in functional gastrointestinal disorders such as irritable bowel syndrome.

GNH USA supplies Mebeverina Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mebeverina Tarbis is an antispasmodic that acts on smooth muscle of the gastrointestinal tract to manage functional bowel conditions.

- Irritable bowel syndrome: reduces abdominal pain, cramping and irregular bowel habits. - Functional bowel disorders: improves overall symptom control and bowel habit regularity. - Spastic colon: alleviates colonic muscle spasms and associated discomfort.

Mebeverina Tarbis may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea - Dry mouth - Headache - Dizziness - Abdominal discomfort - Constipation

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis) - Stevens‑Johnson syndrome or other severe skin rashes - Hepatic injury (elevated liver enzymes, hepatitis) - Angioedema - Cardiac arrhythmia - Significant hypotension

Before initiating therapy, consider the following precautions.

- Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: unknown safety; evaluate risk versus benefit. - Renal impairment: dose adjustment may be required; monitor renal function. - Elderly patients: increased susceptibility to anticholinergic effects; monitor closely. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Mebeverina Tarbis can interact with several drug classes; monitoring is advised.

Major Interactions (Avoid): - CYP3A4 inhibitors: may increase mebeverine plasma concentrations. - Strong anticholinergic agents: additive antispasmodic effect could lead to excessive smooth‑muscle relaxation. - Monoamine oxidase inhibitors: risk of severe hypotension.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., SSRIs): monitor for enhanced gastrointestinal effects. - Diuretics: watch for electrolyte disturbances. - Other antispasmodics: risk of cumulative smooth‑muscle relaxation.